Why This Matters for Your Career
Sanofi is hiring 10 roles related to this product
LEUPROLIDE ACETATE (leuprolide acetate) by Sanofi is acetate, a gnrh agonist, acts as an inhibitor of gonadotropin secretion. Approved for advanced prostate cancer, prostate cancer. First approved in 2001.
acetate, a GnRH agonist, acts as an inhibitor of gonadotropin secretion. Animal studies indicate that following an initial stimulation, continuous administration of leuprolide acetate results in suppression of ovarian and testicular steroidogenesis. This effect was reversible upon discontinuation…
Worked on LEUPROLIDE ACETATE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty
Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)
Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty
Sanofi is hiring 10 roles related to this product